Since elevated NT-proBNP levels may indicate late stage and more severe RV disease, and RV evaluation by echocardiography can be challenging, these findings suggest that CMR may be able to provide a more complete evaluation of RV performance in patients with MS. This evidence concerns the gene NPPB and myeloid sarcoma.